BCR and cancer: Identification of genetic (co)-dependencies is key in preclinical research, as those genes are essential for the fitness of the cancer cell under study and point towards valuable entry points for therapeutic intervention, well-illustrated with the identification of the BCR-ABL fusion kinase in chronic myeloid leukemia that could be specifically blocked by imatinib [76].